MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

The price you pay for Keytruda may depend on factors such as your dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Keytruda.

How much should investors expect sales of Keytruda, the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go before the patents protecting the original version expire. Keytruda ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

The safety profile of the combination therapy remains consistent, with no new adverse effects observed. Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally ...